- Home
- VCSA vs XAIR Comparison
VCSA vs XAIR Comparison
Compare VCSA & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCSA
- XAIR
- Stock Information
- Founded
- VCSA 2009
- XAIR 2011
- Country
- VCSA United States
- XAIR United States
- Employees
- VCSA N/A
- XAIR N/A
- Industry
- VCSA Computer Software: Prepackaged Software
- XAIR Medical/Dental Instruments
- Sector
- VCSA Technology
- XAIR Health Care
- Exchange
- VCSA Nasdaq
- XAIR Nasdaq
- Market Cap
- VCSA 38.6M
- XAIR 34.7M
- IPO Year
- VCSA N/A
- XAIR N/A
- Fundamental
- Price
- VCSA $2.96
- XAIR $0.56
- Analyst Decision
- VCSA Buy
- XAIR Strong Buy
- Analyst Count
- VCSA 4
- XAIR 4
- Target Price
- VCSA $6.08
- XAIR $3.67
- AVG Volume (30 Days)
- VCSA 64.6K
- XAIR 617.0K
- Earning Date
- VCSA 11-07-2024
- XAIR 11-11-2024
- Dividend Yield
- VCSA N/A
- XAIR N/A
- EPS Growth
- VCSA N/A
- XAIR N/A
- EPS
- VCSA N/A
- XAIR N/A
- Revenue
- VCSA $949,936,000.00
- XAIR $2,342,000.00
- Revenue This Year
- VCSA N/A
- XAIR $640.47
- Revenue Next Year
- VCSA N/A
- XAIR $286.81
- P/E Ratio
- VCSA N/A
- XAIR N/A
- Revenue Growth
- VCSA N/A
- XAIR 685.91
- 52 Week Low
- VCSA $2.07
- XAIR $0.30
- 52 Week High
- VCSA $11.70
- XAIR $2.36
- Technical
- Relative Strength Index (RSI)
- VCSA 52.58
- XAIR 59.54
- Support Level
- VCSA $2.67
- XAIR $0.49
- Resistance Level
- VCSA $3.46
- XAIR $0.54
- Average True Range (ATR)
- VCSA 0.28
- XAIR 0.06
- MACD
- VCSA -0.00
- XAIR 0.00
- Stochastic Oscillator
- VCSA 47.11
- XAIR 87.03
About VCSA Vacasa Inc.
Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.